Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 1/20 | 0.60 |
| ▸ | RARB | P10826 | 5/20 | 0.56 |
| ▸ | THRA | P10827 | 4/20 | 0.55 |
| ▸ | THRB | P10828 | 4/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.53 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.50 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31135479 | 0.93 | THRA (0.65) | RARBTHRATHRBALDH1A1HAO1 | |
| SCHEMBL31135461 | 0.93 | THRA (0.65) | RARBTHRATHRBALDH1A1HAO1 | |
| SCHEMBL31135480 | 0.93 | THRA (0.65) | RARBTHRATHRBALDH1A1HAO1 | |
| SCHEMBL13950912 | 0.85 | RARB (0.67) | PLK1RARBTHRATHRBTRPV1 | |
| SCHEMBL2564366 | 0.85 | RARB (0.67) | PLK1RARBTHRATHRBTRPV1 | |
| SCHEMBL2123187 | 0.85 | RARB (0.54) | PLK1RARBTHRATHRBTRPV1 | |
| SCHEMBL1792416 | 0.82 | CYP4A11 (0.74) | PLK1RARBTHRATHRBTRPV1 | |
| SCHEMBL31135470 | 0.82 | ALDH1A1 (0.56) | PLK1CYP4A11ALDH1A1HPGDCYP4F2 | |
| SCHEMBL28494516 | 0.80 | RARB (0.66) | PLK1RARBTHRATHRBTRPV1 | |
| SCHEMBL22505170 | 0.80 | PLK1 (0.65) | PLK1RARBTHRATHRBTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070874-A1 | BENZOYLFORMIC ACID AMIDE DERIVATIVE | KJ CHEMICALS CORPORATION (JP) | 2026-03-12 | — | — | US | disclosed |
| EP-4610249-A1 | BENZOYLFORMIC ACID AMIDE DERIVATIVE | KJ Chemicals Corporation (JP) | 2025-09-03 | — | — | EP | disclosed |
| WO-2024210074-A1 | BENZOYLFORMIC ACID AMIDE DERIVATIVE | ＫＪケミカルズ株式会社 | 2024-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070874-A1 | BENZOYLFORMIC ACID AMIDE DERIVATIVE | CRYAA, BCAT1, BRCA1 | PLK1 4759/4885RARB 585/4885THRA 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.